Evidence map›Paper›PMID 42022843›Full record

ArticleJournal of the Endocrine Society2026

Three-dimensional characterization of adenomyosis in female mice: Toward a novel system for drug efficacy evaluation.

Chihiro Ishizawa, Takehiro Hiraoka, Shizu Aikawa, Xueting He, Daiki Hiratsuka, Yamato Fukui, Mitsunori Matsuo, Tomoko Makabe, Gentaro Izumi, Miyuki Harada and 2 more

Abstract read
In one paragraph

Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chihiro IshizawaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Takehiro HiraokaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.ORCID https://orcid.org/0009-0006-4030-3278
Shizu AikawaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Xueting HeDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Daiki HiratsukaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Yamato FukuiDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Mitsunori MatsuoDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Tomoko MakabeDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Gentaro IzumiDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Miyuki HaradaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Osamu Wada-HiraikeDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.
Yasushi HirotaDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan.ORCID https://orcid.org/0000-0003-0241-9780

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adenomyosis is an intractable gynecological disorder that can give rise to severe pelvic pain, heavy menstrual bleeding, and infertility, predominantly affecting women of reproductive age. The limited efficacy of current pharmacological interventions in certain cases-particularly those resistant to hormone therapies-underscores the urgent need for deeper mechanistic insights and the development of novel therapeutic strategies. Progress in this field, however, has been hampered by the scarcity of suitable experimental models, as adenomyosis is primarily a human disease. In this study, we demonstrate a preclinical platform for therapeutic evaluation using a mouse model of mechanically induced adenomyosis, which recapitulates the key pathological features observed in humans. By integrating high-resolution three-dimensional (3D) tissue imaging, we successfully visualized the invagination and expansion of adenomyosis lesions spatiotemporally. This approach enabled the clear-cut and efficient assessment of progestin efficacy in situ. We propose that the combination of a mechanistically relevant mouse model and advanced 3D histological analysis constitutes a concise and robust system for therapeutic validation and compound screening, thereby facilitating the discovery of effective treatments for adenomyosis.

Indexed as

adenomyosismouse modelprogestinthree-dimensional imaging

Identifiers

PMID42022843
PMCPMC13098150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.